Vesatolimod

本公司产品仅用于科研实验，不得用于人体或动物的临床与诊断

GS-9620 is an effective and specific orally active agonist of Toll-like receptor 7.

Vesatolimod, also known as GS-9620, is a potent and oral agonist of Toll-like receptor-7 developed for finite treatment of chronic hepatitis B viral (HBV) infection, with the goal of inducing a liver-targeted antiviral effect without inducing the adverse effects associated with current systemic interferon-α (IFN-α) therapies. GS-9620 demonstrate interferon-stimulated gene induction without detectable serum interferon at low oral doses. GS-9620 can induce a sustained antiviral response in the woodchuck model of CHB.

GS-9620; GS 9620; GS9620; Vesatolimod

Others

Other Targets

TLR7

Inflammation/Immunology

——

1228585-88-3

410.51

C22H30N6O2

98%

DMSO : 4.8 mg/mL. 11.69 mM;

CCCCOc1nc2c(c(n1)N)NC(=O)CN2Cc1cc(ccc1)CN1CCCC1

4-amino-2-butoxy-8-(3-(pyrrolidin-1-ylmethyl)benzyl)-7,8-dihydropteridin-6(5H)-one

(-20℃)

With Ice Pack

≥ 2 years